Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00629681 |
The purpose of this study is to assess the efficacy and safety of pregabalin for the treatment of diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN)
Condition | Intervention | Phase |
---|---|---|
Neuralgia, Postherpetic Diabetic Neuropathies |
Drug: Pregabalin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Efficacy and Safety of Pregabalin in an Open-Label, Non-Comparative, Flexible-Dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia |
Estimated Enrollment: | 300 |
Study Start Date: | November 2004 |
Study Completion Date: | February 2006 |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Pregabalin
Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion Criteria:
Germany | |
Pfizer Investigational Site | |
Celle, Germany, 29221 | |
Pfizer Investigational Site | |
Ludwigshafen, Germany, 67069 | |
Pfizer Investigational Site | |
Wiesbaden, Germany, 65191 | |
Pfizer Investigational Site | |
Goeppingen, Germany, 73033 | |
Pfizer Investigational Site | |
Mainz, Germany, 55116 | |
Pfizer Investigational Site | |
Berlin, Germany, 10435 | |
Pfizer Investigational Site | |
Bielefeld, Germany, 33604 | |
Pfizer Investigational Site | |
Berlin, Germany, 13053 | |
Pfizer Investigational Site | |
Luebeck, Germany, 23552 | |
Pfizer Investigational Site | |
Osnabrueck, Germany, 49078 | |
Pfizer Investigational Site | |
Aachen, Germany, 52064 | |
Pfizer Investigational Site | |
Luenen, Germany, 44534 | |
Pfizer Investigational Site | |
Berlin, Germany, 10117 | |
Pfizer Investigational Site | |
Senftenberg, Germany, 01968 | |
Pfizer Investigational Site | |
Leer, Germany, 26789 | |
Pfizer Investigational Site | |
Gera, Germany, 07548 | |
Pfizer Investigational Site | |
Sinsheim, Germany, 74889 | |
Pfizer Investigational Site | |
Erfurt, Germany, 99089 | |
Pfizer Investigational Site | |
Katzhuette, Germany, 98746 | |
Pfizer Investigational Site | |
Marl, Germany, 45768 | |
Pfizer Investigational Site | |
Limburgerhof, Germany, 67117 | |
Pfizer Investigational Site | |
Weimar, Germany, 99425 | |
Pfizer Investigational Site | |
Hildesheim, Germany, 31134 | |
Pfizer Investigational Site | |
Leipzig, Germany, 04103 | |
Pfizer Investigational Site | |
Recklinghausen, Germany, 45657 | |
Pfizer Investigational Site | |
Unterhaching, Germany, 82008 | |
Pfizer Investigational Site | |
Zwoenitz, Germany, 08297 | |
Pfizer Investigational Site | |
Karlsruhe, Germany, 76133 | |
Pfizer Investigational Site | |
Hamburg, Germany, 21073 | |
Pfizer Investigational Site | |
Albstadt, Germany, 72458 | |
Pfizer Investigational Site | |
Muenster, Germany, 48129 | |
Pfizer Investigational Site | |
Surwold, Germany, 26903 | |
Pfizer Investigational Site | |
Erbach, Germany, 64711 | |
Pfizer Investigational Site | |
Ludwigshafen, Germany, 67061 | |
Pfizer Investigational Site | |
Hamburg, Germany, 22607 | |
Pfizer Investigational Site | |
Duisburg, Germany, 47051 | |
Pfizer Investigational Site | |
Karlsruhe, Germany, 76199 | |
Pfizer Investigational Site | |
Muenchen, Germany, 81479 | |
Pfizer Investigational Site | |
Hemsbach, Germany, 69502 | |
Pfizer Investigational Site | |
Deggingen, Germany, 73326 | |
Pfizer Investigational Site | |
Veitsbronn, Germany, 90587 | |
Pfizer Investigational Site | |
Frankfurt, Germany, 60311 | |
Pfizer Investigational Site | |
Hamburg, Germany, 22149 | |
Pfizer Investigational Site | |
Itzehoe, Germany, 25524 | |
Pfizer Investigational Site | |
Holle, Germany, 31188 | |
Pfizer Investigational Site | |
Witten, Germany, 58452 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A0081031 |
Study First Received: | February 26, 2008 |
Last Updated: | April 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00629681 |
Health Authority: | Germany: Landesamt für Gesundheit und Arbeitssicherheit des Landes Schleswig-Holstein |
Neuralgia, Postherpetic Diabetic Neuropathies Neuralgia Diabetes Mellitus Endocrine System Diseases Pregabalin Pain |
Signs and Symptoms Neuromuscular Diseases Peripheral Nervous System Diseases Neurologic Manifestations Endocrinopathy Diabetes Complications |
Sensory System Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases Peripheral Nervous System Agents |
Analgesics Central Nervous System Agents Anticonvulsants Pharmacologic Actions |